Effect of Bilvadi kwath and Arogyavardhini vati in the management of medodushti ( dyslipidemia )

Comparative study to evaluate the efficacy of Bilvadi kwath and Arogyavardhini Vati in the management of Medodushti ~ Dyslipidemia - Nil

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/101262

Enrollment

Registered

2026-01-15

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E789- Disorder of lipoprotein metabolism, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: a) Diagnosed and confirmed cases of dyslipidemia based on investigation. b) Patient with any one or more Lakshana of Medodushti (Kshudra shwasa, Trishna, Nidradhikya, Kshudha atimatra ,Swedadhikya, Daurgandhya, Alpa prana) c) Patients with any one or more of the following parameter Total Cholesterol above 200 mg/dl and upto 300 mg/dl, Triglycerides above 150 mg/dl and upto 300 mg/dl or HDL below 40 mg/dl and uoto 20 mg/dl or LDL above 100 mg/dl and upto 200 mg/dl or VLDL above 30 mg/dl to 60 mg/dl . d) Patients who have not taken any statins for more than 15 days or not taking any allopathic treatment at all . e) Patient above 21 and below 60 years of age either sex who will fulfil the criteria of diagnosis. f) Patients willing and able to participate for trial. g) Patients having controlled Diabetes and Hypertension. h)Patients who are ready to give consent with firm home address and contact number which is readily accessible during course of trial.

Exclusion criteria

Exclusion criteria: a) Patient not willing for the trial. b) Patient with Hypertension (BP more than 160/100mm of Hg) c) Patient having illness like uncontrolled Diabetes mellitus, Tuberculosis, Carcinoma, or major illness like renal or Liver disorders. d) Patient having past-history of Myocardial Infarction, Unstable angina, and congestive cardiac failure. e) Patient below 20 years and above 60 years of age. f) History of hypersensitivity to any trial drug or their ingredients. g)Pregnant females and lactating mothers.

Design outcomes

Primary

Measure	Time frame
Reduction in the Serum Triglycerides levelTimepoint: Day 1,30,45	—

Secondary

Measure	Time frame
Reduction in the total Serum Cholesterol, Serum LDL Cholesterol, Serum VLDL Cholesterol and improvement in serum HDL level . Subjective improvement in symptoms of Medodushti is the secondary outcome. Timepoint: Day 1,30,45	—

Countries

India

Contacts

Public ContactProf Dr Atal Bihari Trivedi

Chaudhary Brahm Prakash Ayurved Charak Sansthan

abdratal8@gmail.com9958046550

Outcome results